LDL Cholesterol Reduction Following Ezetimibe Initiation
Low-density Lipoprotein Cholesterol Reduction Following Ezetimibe Initiation: Patterns of Treatment Response
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Cardiovascular Risk
- LDL Cholesterol
At a glance
- Phase
- Phase 4
- Study type
- Interventional
- Sponsor
- Universidade do Porto
- Enrolment target
- 100
- Started
- 1 June 2025
- Main results due
- January 2027
- Study sites
- 1
- Registry updated
- 24 September 2026
Can you take part?
- Ages 18 years to 75 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion criteria: * Age ≥18 and ≤75 years at the time of ezetimibe initiation; * Initiation of ezetimibe as monotherapy or, in patients already treated with statins or other LDL-C-lowering agents, provided that neither the compound nor the dose of the concomitant LDL-C-lowering therapy was modified at the time of ezetimibe initiation. Exclusion criteria: * Absence of indication for ezetimibe therapy as determined by the treating physician; * Initiation of ezetimibe with concomitant modification of statin or other LDL-C-lowering medication type or dosage; * Initiation of ezetimibe/statin combination therapy as the first lipid-lowering regimen.
What this study is about
In the sponsor’s own words, from the registry.
This clinical trial will study why some people have a larger drop in low-density lipoprotein cholesterol (LDL-C), known as "bad cholesterol," after starting ezetimibe. Ezetimibe is a medicine used to lower cholesterol when current treatment is not enough. Adults aged 18 to 75 years who need additional cholesterol treatment will take ezetimibe, either alone or added to their usual stable medication. Researchers will examine whether diet, salt intake, physical activity, and personal health factors influence how much LDL-C levels fall after treatment. Participants will have blood tests before and after starting ezetimibe, complete diet and activity questionnaires, and provide a 24-hour urine sample. The goal is to help doctors better understand who benefits most from ezetimibe and improve personalized cholesterol treatment.
Study sites(1)
Unidade Local de Saúde São João
Porto, Portugal
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07839741. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me